This article was originally published in The Rose Sheet
Executive SummaryMatthias Waehren tapped as CFO effective Aug. 15, replacing long time CFO Othmar Vock, who plans to retire at the end of the year, Swiss fragrance and flavors company announces June 15. Currently with Dutch company DSM Nutritional Products, Waehren formerly worked for Roche, Givaudan notes. Vock has been CFO since 1994...
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.